Trial Profile

Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danvatirsen (Primary) ; Durvalumab (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Sponsors AstraZeneca

06 May 2025 Planned End Date changed from 30 Apr 2025 to 30 Aug 2025.
06 May 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Aug 2025.
22 Feb 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com